mexiletine has been researched along with Eulenburg Disease in 13 studies
Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.
mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effectiveness of mexiletine in nondystrophic myotonia using an aggregated N-of-1 trials design and compare results between this innovative design and a previously conducted RCT." | 7.88 | Effect of Mexiletine on Muscle Stiffness in Patients With Nondystrophic Myotonia Evaluated Using Aggregated N-of-1 Trials. ( Drost, G; Griggs, RC; Groenewoud, HM; Matthews, E; Raaphorst, J; Saris, CGJ; Schouwenberg, BJ; Statland, JM; Stegeman, DF; Stunnenberg, BC; Timmermans, J; Trivedi, J; van der Wilt, GJ; van Engelen, BGM; Woertman, W, 2018) |
| "Mexiletine treatment started at 200 mg/day and was up-titrated by 200 mg increment each three days to reach a maximum dose of 600 mg/day for total treatment duration of 18 days for each cross-over period." | 7.01 | Efficacy and safety of mexiletine in non-dystrophic myotonias: A randomised, double-blind, placebo-controlled, cross-over study. ( Behin, A; Bouhour, F; Fontaine, B; Fournier, E; Franques, J; Hézode, M; Lacomblez, L; Magot, A; Nadaj-Pakleza, A; Payan, C; Péréon, Y; Sacconi, S; Vicart, S; Zahr, N, 2021) |
| "To investigate the effectiveness of mexiletine in nondystrophic myotonia using an aggregated N-of-1 trials design and compare results between this innovative design and a previously conducted RCT." | 3.88 | Effect of Mexiletine on Muscle Stiffness in Patients With Nondystrophic Myotonia Evaluated Using Aggregated N-of-1 Trials. ( Drost, G; Griggs, RC; Groenewoud, HM; Matthews, E; Raaphorst, J; Saris, CGJ; Schouwenberg, BJ; Statland, JM; Stegeman, DF; Stunnenberg, BC; Timmermans, J; Trivedi, J; van der Wilt, GJ; van Engelen, BGM; Woertman, W, 2018) |
| " After treatment with mexiletine, cooling and exercise induced almost no muscle weakness and no changes in 23Na MR signal intensity in patients." | 3.73 | Evaluation of patients with paramyotonia at 23Na MR imaging during cold-induced weakness. ( Essig, M; Huttner, HB; Jurkat-Rott, K; Kauczor, HU; Lehmann-Horn, F; Meinck, HM; Nielles-Vallespin, S; Schad, LR; Weber, MA; Wöhrle, JC, 2006) |
| "Mexiletine treatment started at 200 mg/day and was up-titrated by 200 mg increment each three days to reach a maximum dose of 600 mg/day for total treatment duration of 18 days for each cross-over period." | 3.01 | Efficacy and safety of mexiletine in non-dystrophic myotonias: A randomised, double-blind, placebo-controlled, cross-over study. ( Behin, A; Bouhour, F; Fontaine, B; Fournier, E; Franques, J; Hézode, M; Lacomblez, L; Magot, A; Nadaj-Pakleza, A; Payan, C; Péréon, Y; Sacconi, S; Vicart, S; Zahr, N, 2021) |
| "Skeletal muscle ion channelopathies are rare genetic diseases mainly characterized by myotonia (muscle stiffness) or periodic paralysis (muscle weakness)." | 3.01 | Drug repurposing in skeletal muscle ion channelopathies. ( Altamura, C; Campanale, C; Desaphy, JF; Laghetti, P; Saltarella, I, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Vicart, S | 3 |
| Franques, J | 1 |
| Bouhour, F | 1 |
| Magot, A | 1 |
| Péréon, Y | 1 |
| Sacconi, S | 1 |
| Nadaj-Pakleza, A | 1 |
| Behin, A | 1 |
| Zahr, N | 1 |
| Hézode, M | 1 |
| Fournier, E | 1 |
| Payan, C | 1 |
| Lacomblez, L | 1 |
| Fontaine, B | 3 |
| Altamura, C | 3 |
| Saltarella, I | 2 |
| Campanale, C | 2 |
| Laghetti, P | 2 |
| Desaphy, JF | 5 |
| Stunnenberg, BC | 2 |
| LoRusso, S | 1 |
| Arnold, WD | 1 |
| Barohn, RJ | 1 |
| Cannon, SC | 1 |
| Griggs, RC | 2 |
| Hanna, MG | 1 |
| Matthews, E | 2 |
| Meola, G | 1 |
| Sansone, VA | 1 |
| Trivedi, JR | 1 |
| van Engelen, BGM | 2 |
| Statland, JM | 2 |
| Portaro, S | 1 |
| Naro, A | 1 |
| Bramanti, A | 1 |
| Leo, A | 1 |
| Manuli, A | 1 |
| Balletta, T | 1 |
| Trinchera, A | 1 |
| Bramanti, P | 1 |
| Calabrò, RS | 1 |
| Raaphorst, J | 1 |
| Groenewoud, HM | 1 |
| Woertman, W | 1 |
| Stegeman, DF | 1 |
| Timmermans, J | 1 |
| Trivedi, J | 1 |
| Saris, CGJ | 1 |
| Schouwenberg, BJ | 1 |
| Drost, G | 1 |
| van der Wilt, GJ | 1 |
| De Luca, A | 2 |
| Pierno, S | 1 |
| Liantonio, A | 1 |
| Natuzzi, F | 1 |
| Didonna, MP | 1 |
| Ferrannini, E | 1 |
| Jockusch, H | 1 |
| Franchini, C | 1 |
| Lentini, G | 1 |
| Corbo, F | 1 |
| Tortorella, V | 1 |
| Camerino, DC | 1 |
| Mohammadi, B | 2 |
| Jurkat-Rott, K | 2 |
| Alekov, A | 1 |
| Dengler, R | 2 |
| Bufler, J | 1 |
| Lehmann-Horn, F | 3 |
| Weber, MA | 1 |
| Nielles-Vallespin, S | 1 |
| Huttner, HB | 1 |
| Wöhrle, JC | 1 |
| Schad, LR | 1 |
| Kauczor, HU | 1 |
| Essig, M | 1 |
| Meinck, HM | 1 |
| Colazza, GB | 1 |
| Casali, C | 1 |
| Spadaro, M | 1 |
| Cesaria, VD | 1 |
| Pierelli, F | 1 |
| Weckbecker, K | 1 |
| Würz, A | 1 |
| Mansuroglu, T | 1 |
| George, AL | 2 |
| Lerche, H | 1 |
| Mitrovic, N | 1 |
| Kurihara, T | 1 |
| Tortorella, P | 1 |
| De Vito, D | 1 |
| Conte Camerino, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Combining N-of-1 Trials to Estimate Population Clinical and Cost-effectiveness of Drugs Using Bayesian Hierarchical Modeling. The Case of Mexiletine for Patients With Non- Dystrophic Myotonia.[NCT02045667] | Phase 2 | 30 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for mexiletine and Eulenburg Disease
| Article | Year |
|---|---|
Drug repurposing in skeletal muscle ion channelopathies.
Topics: Channelopathies; Dichlorphenamide; Drug Repositioning; Humans; Mexiletine; Muscle, Skeletal; Mutatio | 2023 |
Drug repurposing in skeletal muscle ion channelopathies.
Topics: Channelopathies; Dichlorphenamide; Drug Repositioning; Humans; Mexiletine; Muscle, Skeletal; Mutatio | 2023 |
Drug repurposing in skeletal muscle ion channelopathies.
Topics: Channelopathies; Dichlorphenamide; Drug Repositioning; Humans; Mexiletine; Muscle, Skeletal; Mutatio | 2023 |
Drug repurposing in skeletal muscle ion channelopathies.
Topics: Channelopathies; Dichlorphenamide; Drug Repositioning; Humans; Mexiletine; Muscle, Skeletal; Mutatio | 2023 |
Guidelines on clinical presentation and management of nondystrophic myotonias.
Topics: Acetazolamide; Age of Onset; Carbonic Anhydrase Inhibitors; Chloride Channels; Electrodiagnosis; Ele | 2020 |
Targeted Therapies for Skeletal Muscle Ion Channelopathies: Systematic Review and Steps Towards Precision Medicine.
Topics: Channelopathies; Humans; Hypokalemic Periodic Paralysis; Lamotrigine; Mexiletine; Muscle, Skeletal; | 2021 |
[Paramyotonia congenita].
Topics: Cold Temperature; Diagnosis, Differential; Humans; Mexiletine; Myotonic Disorders; Point Mutation; P | 2001 |
1 trial available for mexiletine and Eulenburg Disease
| Article | Year |
|---|---|
Efficacy and safety of mexiletine in non-dystrophic myotonias: A randomised, double-blind, placebo-controlled, cross-over study.
Topics: Adult; Aged; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Mexiletine; Middle Aged; | 2021 |
8 other studies available for mexiletine and Eulenburg Disease
| Article | Year |
|---|---|
Beyond the muscular involvement in non-dystrophic myotonias: The emerging role of neuromodulation.
Topics: Adult; Analysis of Variance; Anti-Arrhythmia Agents; Electromyography; Evoked Potentials, Motor; Fem | 2018 |
Effect of Mexiletine on Muscle Stiffness in Patients With Nondystrophic Myotonia Evaluated Using Aggregated N-of-1 Trials.
Topics: Adult; Bayes Theorem; Double-Blind Method; Female; Humans; Male; Mexiletine; Models, Statistical; My | 2018 |
New potent mexiletine and tocainide analogues evaluated in vivo and in vitro as antimyotonic agents on the myotonic ADR mouse.
Topics: Action Potentials; Analysis of Variance; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Do | 2004 |
Preferred mexiletine block of human sodium channels with IVS4 mutations and its pH-dependence.
Topics: Anti-Arrhythmia Agents; Cell Line; Cysteine; Exercise; Histidine; Humans; Hydrogen-Ion Concentration | 2005 |
Evaluation of patients with paramyotonia at 23Na MR imaging during cold-induced weakness.
Topics: Adult; Case-Control Studies; Cold Temperature; Female; Humans; Leg; Magnetic Resonance Spectroscopy; | 2006 |
Electro-oculographic findings in an unusual case of paramyotonia congenita.
Topics: Anti-Arrhythmia Agents; Electromyography; Electrooculography; Female; Humans; Mexiletine; Middle Age | 1999 |
Different effects of mexiletine on two mutant sodium channels causing paramyotonia congenita and hyperkalemic periodic paralysis.
Topics: Cell Line; Homeostasis; Humans; Mexiletine; Models, Molecular; Mutation; Myotonic Disorders; Paralys | 2000 |
Gating of myotonic Na channel mutants defines the response to mexiletine and a potent derivative.
Topics: Cell Line, Transformed; DNA Mutational Analysis; Dose-Response Relationship, Drug; Humans; Ion Chann | 2001 |